Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia.
Le Garff-Tavernier M, Herbi L, de Romeuf C, Azar N, Roos-Weil D, Bonnemye P, Urbain R, Leblond V, Merle-Beral H, Vieillard V. Le Garff-Tavernier M, et al. Among authors: de romeuf c. Haematologica. 2015 Apr;100(4):e147-51. doi: 10.3324/haematol.2014.118083. Epub 2014 Dec 31. Haematologica. 2015. PMID: 25552707 Free PMC article. No abstract available.
Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion.
Le Garff-Tavernier M, Herbi L, de Romeuf C, Nguyen-Khac F, Davi F, Grelier A, Boudjoghra M, Maloum K, Choquet S, Urbain R, Vieillard V, Merle-Béral H. Le Garff-Tavernier M, et al. Among authors: de romeuf c. Leukemia. 2014 Jan;28(1):230-3. doi: 10.1038/leu.2013.240. Epub 2013 Aug 20. Leukemia. 2014. PMID: 23958919 No abstract available.
Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E, Davi F, Debré P, Prost JF, Teillaud JL, Merle-Beral H, Vieillard V. Le Garff-Tavernier M, et al. Among authors: de romeuf c. Leukemia. 2011 Jan;25(1):101-9. doi: 10.1038/leu.2010.240. Epub 2010 Oct 26. Leukemia. 2011. PMID: 20975664
Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.
de Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, Jorieux S, Bihoreau N, Behrens CK, Béliard R, Vieillard V, Cazin B, Bourel D, Prost JF, Teillaud JL, Merle-Béral H. de Romeuf C, et al. Br J Haematol. 2008 Mar;140(6):635-43. doi: 10.1111/j.1365-2141.2007.06974.x. Br J Haematol. 2008. PMID: 18302712 Free article.
Improved in vitro and in vivo activity against CD303-expressing targets of the chimeric 122A2 antibody selected for specific glycosylation pattern.
Fournier N, Jacque E, Fontayne A, Derache D, Dupont G, Verhaeghe L, Baptista L, Dehenne A, Dezetter AS, Terrier A, Longue A, Pochet-Beghin V, Beghin C, Chtourou S, de Romeuf C. Fournier N, et al. Among authors: de romeuf c. MAbs. 2018 May/Jun;10(4):651-663. doi: 10.1080/19420862.2018.1451283. Epub 2018 Apr 10. MAbs. 2018. PMID: 29553870 Free PMC article.
The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
Estupina P, Fontayne A, Barret JM, Kersual N, Dubreuil O, Le Blay M, Pichard A, Jarlier M, Pugnière M, Chauvin M, Chardès T, Pouget JP, Deshayes E, Rossignol A, Abache T, de Romeuf C, Terrier A, Verhaeghe L, Gaucher C, Prost JF, Pèlegrin A, Navarro-Teulon I. Estupina P, et al. Among authors: de romeuf c. Oncotarget. 2017 Jun 6;8(23):37061-37079. doi: 10.18632/oncotarget.15715. Oncotarget. 2017. PMID: 28427157 Free PMC article.
Effect of zinc on human IgG1 and its FcγR interactions.
Sibéril S, Ménez R, Jorieux S, de Romeuf C, Bourel D, Fridman WH, Ducancel F, Stura EA, Teillaud JL. Sibéril S, et al. Among authors: de romeuf c. Immunol Lett. 2012 Mar 30;143(1):60-9. doi: 10.1016/j.imlet.2012.02.002. Immunol Lett. 2012. PMID: 22553781
36 results